ACE and COVID-19: While it is still controversial whether RAAS inhibitors are to be administered to COVID-19 patients (Shibata et al., 2020), it is certain that the therapy with ACE inhibitors and angiotensin receptor blockers (ARBs) should definitely not be discontinued in patients with preexisting cardiovascular diseases (de Abajo et al., 2020; Vaduganathan et al., 2020).